Northern Trust Corp Eq Rx, Inc. Transaction History

Northern Trust Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$1.66 - $2.31 $358,739 - $499,209	216,108 Added 8.23%	2,840,563 $6.31 Million
Q2 2023 Aug 11, 2023	BUY	$1.61 - $1.96 $1.39 Million - $1.69 Million	861,122 Added 48.83%	2,624,455 $4.88 Million
Q1 2023 May 15, 2023	SELL	$1.8 - $2.83 $15,881 - $24,969	-8,823 Reduced 0.5%	1,763,333 $3.42 Million
Q4 2022 Feb 13, 2023	BUY	$2.05 - $5.5 $66,506 - $178,431	32,442 Added 1.86%	1,772,156 $4.36 Million
Q3 2022 Nov 14, 2022	BUY	$0.94 - $5.99 $383,272 - $2.44 Million	407,737 Added 30.61%	1,739,714 $8.61 Million
Q2 2022 Aug 12, 2022	BUY	$3.2 - $5.69 $3.02 Million - $5.36 Million	942,346 Added 241.86%	1,331,977 $6.25 Million
Q1 2022 May 13, 2022	BUY	$2.8 - $7.39 $956,037 - $2.52 Million	341,442 Added 708.55%	389,631 $1.61 Million
Q4 2021 Feb 08, 2022	BUY	$5.92 - $9.98 $285,278 - $480,926	48,189 New	48,189 $329,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.